Breast Cancer News

 
 
  • ASTRO 2018Incorrect Survival Prediction Ups Aggressive End-of-Life Care Inaccurate survival predictions increase the risk that terminal cancer patients will receive poor-quality end-of-life care, such as whole-brain radiation therapy, from which they derive no benefit.
  • ASBMR 2018Can Rare Rebound Fractures After Denosumab Therapy Be Avoided? Two studies suggest rare rebound vertebral fractures after stopping denosumab may be averted by giving a potent bisphosphonate and not continuing aromatase inhibitors beyond 6 months of stopping.
  • Vascular Disease Risk a Consideration in Endocrine Therapy for Breast Cancer Whether a female breast cancer survivor receives an aromatase inhibitor (AI) or tamoxifen should be based on the drug's effectiveness against recurrence, but her risk of venous or arterial disease should also be considered, researchers say.
  • ASTRO 2018Radiation Therapy Cuts Recurrence in 'Good Risk' DCIS Whole-breast radiation halved the risk for recurrence in low-risk ductal carcinoma in situ (DCIS), but treatment after surgery needs to part of a physician-patient discussion.
  • ESMO 2018ONJ With Bone-Modifying Agents in Breast Cancer Patients Osteonecrosis of the jaw was reported in metastatic breast cancer patients treated with bone-modifying agents; the incidence was higher with denosumab compared with bisphosphonates.
  • Eating More Organic Food Tied to Lower Cancer Risk A huge observational study from France surveyed adults online about food consumption and then followed them for a mean of 5 years.
  • ESMO 2018Novel PI3K inhibitor for Breast Cancer: Success at Last? A novel and highly selective PI3K inhibitor for breast cancer may succeed where two other similar but unselective drugs failed because of toxicity.
  • ESMO 2018'Outstanding' Ovarian Cancer PFS With Olaparib Maintenance Patients with newly diagnosed advanced ovarian cancer have a marked increase in progression-free survival with maintenance olaparib after successful first-line chemotherapy, phase 3 study data indicates.
  • ESMO 2018Palbociclib in Breast Cancer: New Overall Survival Data Final results from the PALOMA 3 study show that addition of palbociclib to fulvestrant improves overall survival by 7 months, but the result was not statistically significant. So now what?
  • ESMO 2018New Hope in Triple Negative Breast Cancer With Immunotherapy For the first time, a survival benefit with immunotherapy has been shown in breast cancer with atezolizumab plus chemotherapy in triple negative patients.
  • Breast Tomosynthesis Better Than Mammography? A simplified, single-view version of digital breast tomosynthesis may increase the detection of breast cancer over standard digital mammography, with lower radiation exposure, say Swedish scientists.
  • Given Access, Cancer Patients Read Their Doc's Notes When given easy access to their medical records, cancer patients positively report trust in their physicians and better understanding of treatments, diagnosis, and side effects.
  • Oncologist Shortage Predicted in Major US Cities A concerning trend observed in several US cities that could potentially affect cancer care is that the number of oncologists may be insufficient to treat the growing demand.
  • Biomarker May Predict Breast Cancer Relapse NR2F1 expression may indicate whether or not a breast cancer patient's original tumor has metastasized to bone, researchers suggest.
  • Alert FDA Approves Talazoparib in BRCA+ Breast Cancer Compared with standard chemotherapy, the PARP inhibitor extended progression-free survival for patients with advanced BCRA-positive breast cancer.
  • Should Breast Surgery Be Its Own Medical Specialty? In the US, there are medical specialty boards for thoracic surgery, orthopedic surgery, head and neck surgery, colorectal surgery, and surgery for a variety of other organs/systems. But not the breast.
  • ESMO 2018Twitter Widely Used Among Breast Cancer Patients A new exploratory study found that the popular social network Twitter is widely used among breast cancer patients to share personal experiences and information.
  • ESMO 2018CAM Popular, but Cancer Patients Unaware of Risks Two studies involving sarcoma patients show that complementary and alternative medicine (CAM) treatments are popular, and most patients seem to be unconcerned about risks, such as interactions.
  • Cancer Prevention: Don't Smoke, Drink, and Keep Healthy Weight Establishing policies to stop people from smoking tobacco is the number one priority in the latest report from the American Cancer Society's cancer control Blueprint series.
  • ESMO 2018'Revolutionary' Data to Be Presented at ESMO 2018 Evolutions and even revolutions are expected when the latest data in head and neck cancer, renal cell carcinoma, breast cancer, and ovarian cancer are presented at the leading European cancer meeting.
https://pills24.com.ua

steroid-pharm.com/decaver.html

www.steroid-pharm.com